Possibly the most surprising aspect of the US FDA’s novel approvals in 2023 is a steep jump in what has been one of the most stable review metrics for more than a decade: how many times the FDA missed Prescription Drug User Fee Act user fee goal dates for novel approvals.
The Center for Drug Evaluation and Research approved six novel agents after their user fee goal dates had passed, representing...